The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism

British Journal of Haematology

Volumn 151, Issue 4, 2010, Pages 387-396

  Buglio, Daniela ^a   Mamidipudi, Vidya ^b   Khaskhely, Noor M ^a   Brady, Helen ^b   Heise, Carla ^b   Besterman, Jeffrey ^c   Martell, Robert E ^c   MacBeth, Kyle ^b   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CELGENE CORPORATION   (United States)

^c METHYLGENE INC   (Canada)

Author keywords

Bortezomib; Hodgkin lymphoma; MGCD0103; New drugs for lymphoma

Indexed keywords

BORTEZOMIB; CD137 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; JANUS KINASE 3; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; OX40 LIGAND; SALINOSPORAMIDE A; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CYTOKINE RELEASE; DRUG MECHANISM; DRUG POTENTIATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IC 50; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BORONIC ACIDS; CYTOKINES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HODGKIN DISEASE; HUMANS; NF-KAPPA B; PROTEASE INHIBITORS; PYRAZINES; PYRIMIDINES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 77958596106     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08342.x     Document Type: Article

References (25)

1. Baus, D. & Pfitzner, E. (2006) Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. International Journal of Cancer, 118, 1404-1413.
2. Buglio, D., Georgakis, G.V., Hanabuchi, S., Arima, K., Khaskhely, N.M., Liu, Y.J. & Younes, A. (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood, 112, 1424-1433.
3. Catley, L., Weisberg, E., Kiziltepe, T., Tai, Y.T., Hideshima, T., Neri, P., Tassone, P., Atadja, P., Chauhan, D., Munshi, N.C. & Anderson, K.C. (2006) Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood, 108, 3441-3449.
4. Corcoran, L.J., Mitchison, T.J. & Liu, Q. (2004) A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Current Biology, 14, 488-492.
5. Croft, M., So, T., Duan, W. & Soroosh, P. (2009) The significance of OX40 and OX40L to T-cell biology and immune disease. Immunological Reviews, 229, 173-191.
6. Drexler, H.G. (1993) Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leukaemia & Lymphoma, 9, 1-25.
7. Fournel, M., Bonfils, C., Hou, Y., Yan, P.T., Trachy-Bourget, M.C., Kalita, A., Liu, J., Lu, A.H., Zhou, N.Z., Robert, M.F., Gillespie, J., Wang, J.J., Ste-Croix, H., Rahil, J., Lefebvre, S., Moradei, O., Delorme, D., Macleod, A.R., Besterman, J.M. & Li, Z. (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics, 7, 759-768.
8. Georgakis, G.V., Li, Y., Rassidakis, G.Z., Martinez-Valdez, H., Medeiros, L.J. & Younes, A. (2006) Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clinical Cancer Research, 12, 584-590.
9. Gloghini, A., Buglio, D., Khaskhely, N.M., Georgakis, G., Orlowski, R.Z., Neelapu, S.S., Carbone, A. & Younes, A. (2009) Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. British Journal of Haematology, 147, 515-525.
10. Guo, J.J., Li, Q.L., Zhang, J. & Huang, A.L. (2006) Histone deacetylation is involved in activation of CXCL10 upon IFNgamma stimulation. Molecules and Cells, 22, 163-167.
11. Hauser, A.T. & Jung, M. (2009) Assays for histone deacetylases. Current Topics in Medicinal Chemistry, 9, 227-234.
12. Kim, H.S. & Lee, M.S. (2007) STAT1 as a key modulator of cell death. Cellular Signalling, 19, 454-465.
13. Lane, A.A. & Chabner, B.A. (2009) Histone deacetylase inhibitors in cancer therapy. Journal of Clinical Oncology, 27, 5459-5468.
14. Marks, P.A. & Xu, W.S. (2009) Histone deacetylase inhibitors: potential in cancer therapy. Journal of Cellular Biochemistry, 107, 600-608.
15. Mottok, A., Renne, C., Willenbrock, K., Hansmann, M.L. & Brauninger, A. (2007) Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood, 110, 3387-3390.
16. Peh, S.C., Kim, L.H. & Poppema, S. (2001) TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. American Journal of Surgical Pathology, 25, 925-929.
17. Redmond, W.L. & Weinberg, A.D. (2007) Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Critical Reviews in Immunology, 27, 415-436.
18. Vire, B., De Walque, S., Restouin, A., Olive, D., Van Lint, C. & Collette, Y. (2009) Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. PLoS ONE, 4, e7085.
19. Wang, C., Lin, G.H., McPherson, A.J. & Watts, T.H. (2009) Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunological Reviews, 229, 192-215.
20. Weihrauch, M.R., Manzke, O., Beyer, M., Haverkamp, H., Diehl, V., Bohlen, H., Wolf, J. & Schultze, J.L. (2005) Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Research, 65, 5516-5519.
21. Weniger, M.A., Melzner, I., Menz, C.K., Wegener, S., Bucur, A.J., Dorsch, K., Mattfeldt, T., Barth, T.F. & Moller, P. (2006) Mutations of the tumour suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene, 25, 2679-2684.
22. Xu, W.S., Parmigiani, R.B. & Marks, P.A. (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene, 26, 5541-5552.
23. Younes, A., Pro, B., Fanale, M., McLaughlin, P., Neelapu, S., Fayad, L., Wedgwood, A., Buglio, D., Patterson, T., Dubay, M., Li, Z., Martell, R.E., Ward, M.R. & Bociek, R.G. (2007) Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL). Blood (ASH Annual Meeting Abstracts), 110, 2566.
24. Yuan, Z., Rezai-Zadeh, N., Zhang, X. & Seto, E. (2009) Histone deacetylase activity assay. Methods in Molecular Biology, 523, 279-293.
25. Zheng, B., Fiumara, P., Li, Y.V., Georgakis, G., Snell, V., Younes, M., Vauthey, J.N., Carbone, A. & Younes, A. (2003) MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood, 102, 1019-1027.